A Dose Escalating Clinical Trial of the IGF-1 Receptor Inhibitor AXL1717 in Patients With Advanced Cancer
A dose escalating phase Ia-b clinical trial of the IGF-1 receptor inhibitor AXL1717 in patients with advanced cancer.
The objective is to study the safety and pharmacokinetics of AXL1717 and to define an appropriate Phase 2 dose for further studies. This is the first study in man. The study is not designed to show tumor response.
|Study Design:||Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
|Official Title:||A Dose Escalating Phase Ia-b Clinical Trial of the IGF-1 Receptor Inhibitor AXL1717 in Patients With Advanced Cancer: A Prospective, Single Armed, Open Label, Dose-finding Phase Ia-b Study|
- To define and confirm recommended Phase 2 dose
|Study Start Date:||April 2008|
|Primary Completion Date:||May 2011 (Final data collection date for primary outcome measure)|
Phase I study with increasing dosage and treatment duration
Please refer to this study by its ClinicalTrials.gov identifier: NCT01062620
|Uppsala University Hospital|
|Uppsala, Sweden, SE-75185|
|Principal Investigator:||Michael Bergqvist, MD||Uppsala University Hospital|